Nagendran Sukumar 4
4 · Taysha Gene Therapies, Inc. · Filed Dec 1, 2025
Insider Transaction Report
Form 4
Nagendran Sukumar
DirectorPresident and Head of R&D
Transactions
- Exercise/Conversion
Common Stock
2025-11-28$0.70/sh+70,172$49,043→ 1,076,611 total - Exercise/Conversion
Common Stock
2025-11-28$1.71/sh+39,953$68,320→ 1,116,564 total - Sale
Common Stock
2025-11-28$4.75/sh−110,125$523,094→ 1,006,439 total - Exercise/Conversion
Common Stock
2025-12-01$1.71/sh+260,047$444,680→ 1,266,486 total - Sale
Common Stock
2025-12-01$4.51/sh−260,047$1,172,812→ 1,006,439 total - Exercise/Conversion
Employee Stock Option (right to buy)
2025-11-28−70,172→ 222,683 totalExercise: $0.70Exp: 2033-12-14→ Common Stock (70,172 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-11-28−39,953→ 823,664 totalExercise: $1.71Exp: 2034-01-02→ Common Stock (39,953 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2025-12-01−260,047→ 563,617 totalExercise: $1.71Exp: 2034-01-02→ Common Stock (260,047 underlying)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.
- [F3]The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
- [F4]25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.